GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ArriVent BioPharma Inc (NAS:AVBP) » Definitions » Gross Profit

AVBP (ArriVent BioPharma) Gross Profit : $0.00 Mil (TTM As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is ArriVent BioPharma Gross Profit?

ArriVent BioPharma's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. ArriVent BioPharma's gross profit for the trailing twelve months (TTM) ended in Dec. 2024 was $0.00 Mil.

Gross Margin % is calculated as gross profit divided by its revenue. ArriVent BioPharma's gross profit for the three months ended in Dec. 2024 was $0.00 Mil. ArriVent BioPharma's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, ArriVent BioPharma's Gross Margin % for the quarter that ended in Dec. 2024 was N/A%.

ArriVent BioPharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


ArriVent BioPharma Gross Profit Historical Data

The historical data trend for ArriVent BioPharma's Gross Profit can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ArriVent BioPharma Gross Profit Chart

ArriVent BioPharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24
Gross Profit
- - - -

ArriVent BioPharma Quarterly Data
Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Gross Profit Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ArriVent BioPharma's Gross Profit

For the Biotechnology subindustry, ArriVent BioPharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ArriVent BioPharma's Gross Profit Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ArriVent BioPharma's Gross Profit distribution charts can be found below:

* The bar in red indicates where ArriVent BioPharma's Gross Profit falls into.


;
;

ArriVent BioPharma Gross Profit Calculation

Gross Profit is the different between the sale prices and the cost of buying or producing the goods.

ArriVent BioPharma's Gross Profit for the fiscal year that ended in Dec. 2024 is calculated as

Gross Profit (A: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

ArriVent BioPharma's Gross Profit for the quarter that ended in Dec. 2024 is calculated as

Gross Profit (Q: Dec. 2024 )=Revenue - Cost of Goods Sold
=0 - 0
=0.00

Gross Profit for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.

Gross Profit is the numerator in the calculation of Gross Margin. (Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)

ArriVent BioPharma's Gross Margin % for the quarter that ended in Dec. 2024 is calculated as

Gross Margin % (Q: Dec. 2024 )=Gross Profit (Q: Dec. 2024 ) / Revenue (Q: Dec. 2024 )
=(Revenue - Cost of Goods Sold) / Revenue
=0.00 / 0
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.


ArriVent BioPharma  (NAS:AVBP) Gross Profit Explanation

Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.

Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %

1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key

ArriVent BioPharma had a gross margin of N/A% for the quarter that ended in Dec. 2024 => No sustainable competitive advantage


ArriVent BioPharma Gross Profit Related Terms

Thank you for viewing the detailed overview of ArriVent BioPharma's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.


ArriVent BioPharma Business Description

Traded in Other Exchanges
N/A
Address
18 Campus Boulevard, Suite 100, Newtown Square, Philadelphia, PA, USA, 19073
ArriVent BioPharma Inc is a clinical-stage biopharmaceutical company dedicated to the identification, development, and commercialization of differentiated medicines to address the unmet medical needs of patients with cancers. It seeks to utilize the team's deep drug development experience to maximize the potential of the lead development candidate, furmonertinib, and advance a pipeline of novel therapeutics, such as next-generation antibody-drug conjugates, through approval and commercialization in patients suffering from cancer, with an initial focus on solid tumors.